Cargando…
Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
OBJECTIVE: The aim of this study was to find the optimum dosage of dexmedetomidine in Spinal Orthopedic Scoliosis Correction Surgery when used in combination with propofol and remifentanil in American Society of Anesthesiologists (ASA) III patients with severe scoliosis undergoing intraoperative wak...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913085/ https://www.ncbi.nlm.nih.gov/pubmed/35451391 http://dx.doi.org/10.1097/MD.0000000000028993 |
_version_ | 1784667338142908416 |
---|---|
author | Yang, Ting Mudabbar, Muhammad Saqib Chen, Tao Jia, Hong Fu, Qiang Liu, Bin |
author_facet | Yang, Ting Mudabbar, Muhammad Saqib Chen, Tao Jia, Hong Fu, Qiang Liu, Bin |
author_sort | Yang, Ting |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to find the optimum dosage of dexmedetomidine in Spinal Orthopedic Scoliosis Correction Surgery when used in combination with propofol and remifentanil in American Society of Anesthesiologists (ASA) III patients with severe scoliosis undergoing intraoperative wake-up test. MATERIALS AND METHODS: We selected a total of 60 ASA III ≤40 years old patients who underwent Spinal Orthopedic Scoliosis Correction Surgery (SOSCS) and randomized them into groups A, B, and C. Group A was administered 0.2 μg/(kg·h) of dexmedetomidine, group B 0.3 μg/(kg·h), and group C 0.4 μg/(kg·h). The main parameters monitored were: wake-up time; wake-up quality; adverse effects that occur while the patient is awake; postoperative awareness of intraoperative wake-up test; heart rate (HR); mean arterial pressure (MAP); and oxygen saturation (SpO(2)). Values of these parameters were monitored at 7 timestamps separated by 5 minutes >30 minutes. RESULTS: Group B had a higher MAP at 10 minutes before wake-up (P = .03) and at the moment of wake-up (P = .04) than group A. The Wake-up time of group A was 14.95 ± 7.42 minutes, group B was 14.7 ± 6.52 minutes, which was significantly shorter than that of group C 21.3 ± 10.02 minutes (P = .02). The wake-up quality was excellent. All other parameters had no significant statistical differences. CONCLUSION: Doses of 0.2 to 0.3 μg/(kg·h) have shorter wake-up time and fewer hemodynamic fluctuations compared to 0.4 μg/(kg·h). |
format | Online Article Text |
id | pubmed-8913085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-89130852022-03-15 Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial Yang, Ting Mudabbar, Muhammad Saqib Chen, Tao Jia, Hong Fu, Qiang Liu, Bin Medicine (Baltimore) 3300 OBJECTIVE: The aim of this study was to find the optimum dosage of dexmedetomidine in Spinal Orthopedic Scoliosis Correction Surgery when used in combination with propofol and remifentanil in American Society of Anesthesiologists (ASA) III patients with severe scoliosis undergoing intraoperative wake-up test. MATERIALS AND METHODS: We selected a total of 60 ASA III ≤40 years old patients who underwent Spinal Orthopedic Scoliosis Correction Surgery (SOSCS) and randomized them into groups A, B, and C. Group A was administered 0.2 μg/(kg·h) of dexmedetomidine, group B 0.3 μg/(kg·h), and group C 0.4 μg/(kg·h). The main parameters monitored were: wake-up time; wake-up quality; adverse effects that occur while the patient is awake; postoperative awareness of intraoperative wake-up test; heart rate (HR); mean arterial pressure (MAP); and oxygen saturation (SpO(2)). Values of these parameters were monitored at 7 timestamps separated by 5 minutes >30 minutes. RESULTS: Group B had a higher MAP at 10 minutes before wake-up (P = .03) and at the moment of wake-up (P = .04) than group A. The Wake-up time of group A was 14.95 ± 7.42 minutes, group B was 14.7 ± 6.52 minutes, which was significantly shorter than that of group C 21.3 ± 10.02 minutes (P = .02). The wake-up quality was excellent. All other parameters had no significant statistical differences. CONCLUSION: Doses of 0.2 to 0.3 μg/(kg·h) have shorter wake-up time and fewer hemodynamic fluctuations compared to 0.4 μg/(kg·h). Lippincott Williams & Wilkins 2022-03-11 /pmc/articles/PMC8913085/ /pubmed/35451391 http://dx.doi.org/10.1097/MD.0000000000028993 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 3300 Yang, Ting Mudabbar, Muhammad Saqib Chen, Tao Jia, Hong Fu, Qiang Liu, Bin Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial |
title | Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial |
title_full | Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial |
title_fullStr | Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial |
title_full_unstemmed | Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial |
title_short | Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial |
title_sort | dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: a randomized controlled trial |
topic | 3300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913085/ https://www.ncbi.nlm.nih.gov/pubmed/35451391 http://dx.doi.org/10.1097/MD.0000000000028993 |
work_keys_str_mv | AT yangting dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial AT mudabbarmuhammadsaqib dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial AT chentao dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial AT jiahong dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial AT fuqiang dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial AT liubin dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial |